Jessica Hopfield, Ph.D. is a former partner of McKinsey & Company in their Global Pharmaceutical and Medical Device practice. While at McKinsey from 1995-2009, she served clients across pharmaceutical, biotech, medical device and consumer industries with a focus on strategy, R&D management and marketing.
Dr. Hopfield serves as an Independent Director of Insulet Corporation, a global medical device company which manufactures and sells the Omnipod(r) insulin patch pump and partners with pharmaceutical companies to deliver subcutaneous drugs across multiple therapeutic areas. She serves on Insulet’s Audit and Compensation Committees.
Dr. Hopfield also serves on the Board of Directors of Editas Medicine, a leading genome editing company, focused on translating the power and potential of CRISPR genome editing systems into treatments for people living with serious disease. Dr. Hopfield serves on the Audit and Nominating and Governance Committees of the Board.
She also serves on the Board of Directors of Radius Health, a biopharmaceutical company which develops and commercializes innovative endocrine therapies to treat osteoporosis and cancer.
She founded J Hopfield Consulting in 2010 to provide strategic guidance and capital to start-up technology firms seeking to commercialize intellectual property. She previously held management positions at Merck Sharp and Dohme in Clinical Development, Outcomes Research, and Marketing.
Dr. Hopfield earned an M.B.A. from Harvard Graduate School of Business Administration as a Baker Scholar, a Ph.D. in neuroscience/biochemistry from the Rockefeller University, and a B.S. from Yale College.
Page last updated: August 22, 2019